Two new phenylpiperazines with atypical antipsychotic potential

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 5749-5753

  Tomić, Mirko ^a   Ignjatović, Djurdjica ^a   Tovilović, Gordana ^a   Andrić, Deana ^b   Roglić, Goran ^b   Kostić Rajačić, Sladjana ^c  

^a Institute for Biological Research   (Serbia)

^b Faculty of Chemistry   (Serbia)

^c Institute for Chemistry   (Serbia)

Author keywords

Arylpiperazines; Atypical antipsychotics; Dopamine receptors; Serotonin receptors

Indexed keywords

3 PROPOXYBENZIMIDAZOLE 2 THIONE DERIVATIVE; 3 PROPOXYBENZIMIDAZOLE DERIVATIVE; ALPHA 1 ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PHENYLPIPERAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MALE; NONHUMAN; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; PIPERAZINES; RATS;

MUS; RATTUS; RODENTIA;

EID: 34648847078     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.066     Document Type: Article

References (26)

1. Taylor D.M. Schizophrenia in Focus (2006), Pharmaceutical Press, London, Chicago Chapters 1-8, 14-16.
2. Sramek J.J., Cutler N.R., Kurtz N.M., Murphy M.F., and Carta A. Optimizing the Development of Antipsychotic Drugs (1997), Wiley, Chichester Chapters 2,3
3. Tandon R., and Jibson M.D. Psychoneuroendocrinology 28 (2003) 9
4. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Mol. Psychiatry 10 (2005) 79
5. Meltzer H.Y., Matsubara S., and Lee J.C. Psychopharmacol. Bull. 25 (1989) 390
6. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Prog. Neuropsychopharmacol. 27 (2003) 1159
7. Meltzer H.Y. Curr. Op. Pharmacol. 4 (2004) 53
8. Ichikawa J., and Meltzer H.Y. Brain Res. 858 (2000) 252
9. Bantick R.A., Deakin J.F., and Grasby P.M. J. Psychopharmacol. 15 (2001) 37
10. Grunder G., Wetzel H., Hammes E., and Benkert O. Psychopharmacology (Berl.) 111 (1993) 123
11. Maj J., Kolodziejczyk K., Rogóz Z., and Skuza G. J. Neural. Transm. 103 (1996) 627
12. Dukić S., Kostić-Rajačić S., Dragović D., Šoškić V., and Joksimović J. J. Pharm. Pharmacol. 49 (1997) 1036
13. Kostić-Rajačić S., Šoškić V., and Joksimović J. Arch. Pharm. (Weinheim) 331 (1998) 22
14. Tomić M., Kundaković M., Butorović B., Vasilev V., Dragović D., Roglić G., Ignjatović D., Šoškić V., and Kostić-Rajačić S. Pharmazie 58 (2003) 677
15. Tomić M., Kundaković M., Butorović B., Janać B., Andrić D., Roglić G., and Ignjatović D. Bioorg. Med. Chem. Lett. 14 (2004) 42
16. Šukalović V., Andrić D., Roglić G., Kostić-Rajačić S., Schrattenholz A., and Šoškić V. Eur. J. Med. Chem. 40 (2005) 481
17. 4OS.
18. 4O.
19. Vogel G.H. In: Vogel G.H. (Ed). Drug Discovery and Evaluation-Pharmacological Assays. 2nd ed. (2002), Springer-Verlag, Berlin, Heidelberg 500-543
20. 7b.
21. Open-field test. A total of 84 adult CPU mice males (30-40 g) were divided into 14 experimental groups (each consisting of 6 animals). Six groups were used to evaluate the effects of test compounds on spontaneous locomotor activity. Compounds 8a and 9a were originally dissolved in DMSO (final conc. up to 2%), diluted with saline, and ip injected (1.0 mg, or 10.0 mg in 2.0 ml per kg bw) 20 min before another injection of saline. The controls received first saline/DMSO and the comparison drug's group was primary treated with clozapine (5 mg/kg). Remaining eight groups of mice were employed to assess the effects of the first treatment on amphetamine-induced hyperactivity. They received (by the same schedule as above) either 1.0 mg, 4.0 mg, or 10.0 mg of 8a or 9a, saline/DMSO or clozapine (5 mg/kg), 20 min prior to d-AMPH sulphate (3.0 mg/kg). Each animal was positioned in the center of the plastic open-box (40 × 40 × 30 cm) immediately after the second injection and for the next 15 min they were allowed to adapt to the environment. The test room with the acoustic isolation was dimly illuminated (indirect 2 × 40 W light). During the following 60 min interval, locomotion was registered by a web-camera connected to PC and controlled by ANY-maze software (ANY-maze Video Tracking System 4.30, Stoelting Co., USA). The same program was also used to calculate two parameters chosen to illustrate total animal locomotion. (1) Time of activity (in seconds) was the sum of periods when animals moved in space. (2) Total head distance (in meters) demonstrated both the total locomotion in space and the head movements made in place, also representing a measure of some stereotype behaviors. Crude data was analyzed by GraphPad Prysm (4.00) using one-way ANOVA followed by Bonferroni's multiple group comparison test.
22. Wadenberg M.L., Hertel P., Fernholm R., Hygge Blakeman K., Ahlenius S., and Svensson T.H.J. Neural. Transm. 107 (2000) 1229
23. Svensson T.H. Progr. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1145
24. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Neuropsychopharmacology 28 (2003) 1400
25. DeLeon A., Patel N.C., and Crismon M.L. Clin. Therapeutics 26 (2004) 650
26. Roth B.L., Sheffler D.J., and Kroeze W.K. Nat. Rev. Drug Discovery 3 (2004) 353